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Abstract	The	goal	of	this	research	was	to	express	and	purify	Cellular	Retinoic	Acid	Binding	Protein	Type	1	(CRABP1).	CRABP1	binds	to	retinoic	acid	in	the	cell	and	shuttles	the	retinoic	acid	from	one	area	in	the	cell	to	another.	The	overproduction	of	CRABP1	appears	to	be	problematic	because	it	can	sequester	the	retinoic	acid	and	prevent	it	from	regulating	gene	expression.	Previous	studies	have	shown	that	increased	levels	of	CRABP1	can	result	in	tumor-promoting	activity	and	disruption	of	lipid	biology	in	the	cell.	Our	objective	was	to	express	this	protein	in	an	inducible	bacterial	system,	so	that	we	could	purify	the	protein	and	characterize	its	functions	in	vitro.	Initial	work	to	express	the	protein	using	a	cloning	vector	and	inducible	promoter	was	unsuccessful;	however,	we	were	able	to	clone	the	
crabp1	gene	into	other	expression	vectors	and	will	test	transformants	for	inducible	expression	in	future	experiments.					
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Introduction	One	in	eight	women	will	contract	invasive	breast	cancer	over	the	course	of	her	lifetime.	In	the	United	States	alone,	it	is	estimated	that	in	2020,	approximately	276,480	women	will	be	diagnosed	with	invasive	breast	cancer,	plus	another	48,530	women	will	be	diagnosed	with	non-invasive	breast	cancer.	Breastcancer.org,	2019) It	is	estimated	that	30%	of	cancers	diagnosed	in	women	this	year	will	be	breast	cancer.	Besides	skin	cancer,	breast	cancer	is	the	most	come	type	of	cancer	among	women	(“Breastcancer.org,	2020)	These	startling	numbers	beg	the	question,	what	more	can	be	done?	With	one	of	the	highest	incidences,	more	research	needs	to	be	done	on	breast	cancer	to	find	a	cure.	 Cancer	often	arises	from	mutations	in	the	cellular	genome.	This	mutated	genetic	information	can	lead	to	the	production	of	cell	cycle	proteins	that	either	lose	specific	functions	or	have	altered	functions,	and	these	mutations	may	result	in	the	rapid	overgrowth	and	division	of	cells.	Specifically,	there	are	two	groups	of	genes	that	express	cell	cycle	proteins.	The	first	group	is	called	proto-oncogenes.	These	are	genes	that	produce	proteins	that	encourage	cell	proliferation	and	inhibit	cell	death	(Does,	2004).	The	other	group	is	tumor	suppressors.	These	genes	produce	proteins	that	prevent	cell	proliferation	and	induce	cell	death.	These	two	groups	work	in	opposition	to	regulate	cell	growth.	One	way	in	which	cells	become	cancerous	is	with	the	mutation	of	a	proto-oncogene	into	an	oncogene,	causing	cell	growth	to	accelerate	without	control.	Mutations	of	proto-oncogenes	are	usually	found	to	be	dominant.	This	means	that	only	one	out	of	the	two	copies	of	the	gene	within	the	cell	needs	to	be	mutated	in	order	to	get	mutated	function.	If	these	mutations	occur	in	germ	line	cells,	egg	cells,	or	sperm	cells,	they	will	get	passed	down	to	offspring	(Does,	2004).	
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Mutations	could	also	occur	in	tumor	suppressor	genes.	Mutations	in	these	genes	cause	a	loss	of	function	of	the	resulting	proteins.	This	means	that	these	proteins	are	no	longer	able	to	inhibit	cell	proliferation,	and	the	proto-oncogenes	or	oncogenes	are	able	to	cause	mass	cell	divisions	without	the	regulation	of	the	tumor	suppressors	(Does,	2004).	These	mutations	can	also	be	hereditary,	but	they	are	recessive	so	the	mutation	would	have	to	be	present	in	both	copies	of	the	gene	to	cause	an	alteration	in	function.	This	could	happen	by	the	first	mutated	copy	being	inherited	and	the	second	one	mutating	itself,	or	both	could	mutate	without	hereditary	influence.	BReast	CAncer	1	and	BReast	CAncer	2	(BRCA1	and	BRCA2)	gene	mutations	are	a	common	example	of	a	hereditary	mutation	that	can	lead	to	breast	cancer	(Does,	2004).	Both	of	these	genes	are	tumor	suppressors.	BRCA1	plays	a	role	in	cell	cycle	control,	while	BRCA2	is	involved	in	DNA	repair	processes.	These	are	both	crucial	functions	that	when	disabled	lead	to	breast	cancer	(Does,	2004).	Lastly,	mutations	can	occur	in	DNA	repair	genes.	Mutations	in	a	cell’s	DNA	may	arise	spontaneously	from	ultraviolet	radiation,	ionizing	radiation,	chemical	damage,	or	mistakes	made	during	DNA	replication.	Without	functional	DNA	repair	proteins,	these	gene	defects	could	lead	to	an	increased	risk	of	developing	cancer	(Does,	2004).	Although	mutations	to	proto-oncogenes,	tumor	suppressors,	and	the	DNA	repair	machinery	can	lead	to	breast	cancer,	other	proteins	may	also	be	associated	with	breast	cancer	tumorigenesis.	One	such	protein	is	Cellular	Retinoic	Acid	Binding	Protein	1	(CRABP1).	CRABP1’s	normal	function	is	to	shuttle	retinoic	acid,	a	vitamin	A	derivative,	around	the	cells	(Connolly	et	al.,	2013).	Retinoic	acid	plays	an	important	part	in	cell	differentiation,	regulation	of	growth,	and	apoptosis	(Connolly	et.	al.,	2013).	It	has	been	observed	that	the	overexpression	of	CRABP1	has	been	associated	with	breast	cancer	
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incidence	(Liu	et.	al.,	2015).	In	this	section	I	will	discuss	the	function	of	retinoic	acid,	the	role	of	CRABP1,	how	CRABP1	is	thought	to	be	related	to	breast	cancer,	and	how	we	hope	to	further	investigate	the	role	of	this	protein	in	disease	progression.		
 CRABP1	binds	to	retinoic	acid,	which	is	a	metabolite	of	Vitamin	A.	Vitamin	A	is	a	very	important	vitamin	for	human	survival	and	is	required	for	development	in	the	embryo	through	adulthood.	In	fact,	not	getting	enough	vitamin	A	can	lead	to	vitamin	A	deficiency	(VAD),	and	this	can	cause	a	wide	variety	of	defects	including	intellectual	and	physical	disabilities.	In	adults,	a	lack	in	vitamin	A	can	impair	things	like	vision,	reproduction,	and	the	immune	system	(Tanoury	et	al.,	2013).	Retinoic	acid	and	other	retinoid	derivatives	regulate	processes	like	cell	proliferation,	cell	differentiation,	apoptosis,	the	inflammatory	response,	embryo	growth,	and	functions	in	the	nervous	and	immune	systems	(Napoli	et	al.,	2017).		This	means	that	retinoic	acid	and	its	derivatives	play	a	key	role	in	stopping	the	overgrowth	of	cells	and	keep	the	cell	cycle	in	check.	For	this	reason,	there	has	been	extensive	research	done	on	retinoic	acid	for	cancer	treatment.	The	Food	and	Drug	Administration	has	approved	the	use	of	retinoic	acid	as	a	leukemia	and	lymphoma	therapy	(Chen	et	al.,	2014).	Retinoic	acid	has	the	ability	to	inhibit	tumor	growth,	the	formation	of	new	blood	vessels,	and	metastasis	(Chen	et	al.,	2014).	 
	 Many	proteins	are	involved	in	the	transport	of	retinoids	throughout	the	cell,	including	cellular	retinol	binding	proteins	1	and	2	(CRBP1	and	CRBP2),	CRABP2,	and	FABP5	(fatty	acid	binding	protein	5).	These	proteins	shuttle	retinoids	from	one	cellular	compartment	to	another.	CRBP1	carries	retinol	and	retinal	in	various	cell	types,	while	CRBP2	also	carries	retinol	and	retinal,	but	is	specific	to	cells	of	the	small	intestine.	CRABP2	
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carries	retinoic	acid	isomers	to	the	skin,	uterus,	and	ovaries.	FABP5	shuttles	long-chain	fatty	acids	and	retinoic	acid	in	many	types	of	cells,	but	specifically	liver	cells	(Napoli	et	al.,	2017).			 Because	retinoic	acid	is	a	largely	hydrophobic	molecule,	it	is	not	very	soluble	in	aqueous	compartments	of	the	cell.	In	order	for	the	retinoic	acid	to	travel	through	the	cell,	it	binds	to	CRABP1	and	is	shuttled	around	within	the	cell.	CRABP1	is	capable	of	accommodating	retinoic	acid	in	a	non-polar	binding	pocket	(Napoli	et	al.,	2017).	The	CRABP1	protein	is	structured	like	a	barrel	(Figure	1).	It	has	hydrophobic	amino	acids	facing	the	interior	of	the	barrel	where	the	hydrophobic	tail	of	the	retinoic	acid	molecule	binds.	The	outside	of	the	barrel	has	polar	amino	acids	lining	it	so	that	it	can	interact	with	its	aqueous	surroundings.	The	carboxylate	side	of	the	retinoic	acid	molecule	hydrogen	bonds	to	the	polar	amino	acids	in	the	binding	pocket.			 CRABP1	has	two	hypothesized	roles.	First,	CRABP1	has	a	high	affinity	for	cytoplasmic	retinoic	acid.		Researchers	hypothesized	that	CRABP1	decreases	the	concentration	of	available	retinoic	acid	for	the	nucleus	while	also	deactivating	it.	When	CRABP1’s	expression	was	altered	alterations	and	mutations	were	executed,	researchers	observed	that	high	concentrations	of	CRABP1	caused	cells	have	a	decrease	in	responsiveness	to	retinoic	acid.	That	is,	cells	were	less	affected	by	retinoic	acid	as	a	gene	expression	regulator	with	an	increase	of	cellular	levels	of	CRABP1	(Wei,	2012).	Another	theory	proposed	for	CRABP1’s	function	is	that	it	aids	in	the	conversion	of	retinoic	acid	into	other,	more	polar,	derivatives	that	help	regulate	gene	expression	by	binding	to	retinoic	acid	receptors	in	the	nucleus	(Wei,	2012).	This	pathway	is	not	fully	understood,	but	when	cellular	levels	of	CRABP1	were	increased	in	one	type	of	cell	it	caused	an	increase	in	the	
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conversion	of	retinoic	acid	into	its	other	derivatives.	This	could	mean	CRABP1	is	at	least	partly	responsible	for	the	modification	of	retinoic	acid	in	cells	(Wei,	2012).			 To	further	test	the	importance	of	CRABP1,	researchers	disabled	the	gene	in	young,	developing	mice.	These	young	mice	then	died.	Contradictory	to	this,	when	CRABP1	was	disabled	in	normal	adult	mice,	few	changes	were	seen	in	the	health	of	the	mice(Wei,	2012).	It	was	hypothesized,	however,	that	the	adult	mice	may	have	had	and	alternative	mechanism	for	the	transportation	and	regulation	of	retinoic	acid	and	its	pathway	(Wei,	2012).	This	could	suggest	that	CRABP1,	which	we	know	shuttles	retinoic	acid	into	the	cells,	is	needed	much	more	in	developing	organisms.			 Researchers	also	found	that	CRABP1	promotes	pregnancy-associated	breast	cancer	and	have	hypothesized	that	changes	in	glandular	structure	during	the	stages	of	pregnancy,	specifically	during	lactation,	may	have	an	important	role	in	pregnancy-associated	breast	cancer	(McCready	et	al.,	2014).	Mammary	adipose	stromal	cells	were	isolated	from	mice	at	different	stages	of	mammary	development:	post-pubertal,	pregnancy,	lactation,	involution	(remodeling	of	the	mammary	gland	back	to	its	pre	pregnant	state),	and	regression.	It	was	found	that	ASCs	that	were	acquired	during	lactation	(ASC-Ls),	but	not	other	stages	of	mammary	development,	promoted	the	growth	of	carcinoma	cells	(McCready	et	al.,	2014).	Upon	comparing	gene	expression	of	these	cells	to	the	cells	in	other	developmental	stages,	it	was	also	determined	that	the	CRABP1	gene	was	more	highly	expressed	in	ASC-Ls	compared	to	ASCs	at	other	developmental	stages.	Inhibition	of	crabp1	expression	in	ASC-Ls	restored	its	ability	to	accumulate	lipids,	and	incubation	of	these	inhibited	cells	with	carcinoma	cells	resulted	in	smaller,	slower	growing	tumor	cells.	These	findings	suggest	that	CRABP1	
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overexpression	in	ASC-Ls	has	some	association	with	the	onset	or	progression	of	pregnancy-associated	breast	cancer	(McCready	et	al.,	2014).			From	the	experiments	described	above,	there	appears	to	be	a	link	between	the	expression	of	CRABP1	and	breast	cancer.	The	relationships	between	CRABP1,	lipid	binding	and	lipid	sequestration	in	breast	cancer	is	unclear.	In	an	effort	to	understand	CRABP1’s	function	in	these	processes	more	completely,	our	research	objective	was	to	conduct	biochemical	assays	with	purified	CRABP1	protein.	This	thesis	discusses	our	approach	to	express	CRABP1	and	to	clone	the	gene	into	several	alternative	expression	plasmids.																		
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Methods	
Expression	of	CRABP1	A	pBlueScript	(pBS)	plasmid	containing	the	crabp1	gene	was	obtained	from	the	Tabin	Laboratory	at	Harvard	Medical	School	(Boston,	MA).	The	crabp1	gene	is	under	the	control	of	a	lac	operator,	and	its	expression	can	be	induced	in	the	presence	of	isopropyl	β-D-1-thiogalactopyranoside	(IPTG).	The	plasmid	was	transformed	into	DH5a	cells	(see	Table	1	for	antibiotic	resistance),	and	a	mini	prep	of	the	cells	was	done	to	yield	a	concentrated	amount	of	the	CRABP1	plasmid	DNA.	Upon	completion	of	the	miniprep,	the	concentration	was	measured.		The	plasmid	was	then	transformed	into	BL21(DE3)	cells,	cells	that	typically	yield	large	amounts	of	expressed	protein.	To	induce	the	expression	of	CRABP1	in	these	cells,	an	overnight	culture	of	BL21(DE3)	cells	in	Luria	broth	(LB)	was	first	made.	Overnight	cultures	were	made	by	using	a	sterile	flask	of	LB	broth	(100mL).	100	μL	of	ampicillin	(100	mg/ml)	was	put	into	the	flask.	A	sterile	inoculating	loop	was	used	to	pick	up	multiple	colonies	from	the	respective	plated	culture	and	inserted	into	the	flask	of	LB	broth.	The	flask	was	then	put	in	a	shaking	incubator	at	37°C	at	200	rpm	for	about	12	hours.	A	sample	was	taken	from	this	culture	and	diluted	to	a	ratio	of	1:100	in	fresh	media	(100	mL).	This	new	sample	grew	to	an	optical	density	(OD600)	of	approximately	0.5.	Once	the	sample	reached	optimum	density,	1	mL	of	1	mM	IPTG	was	added	to	the	media	to	induce	gene	expression,	and	the	cells	were	induced	at	25°C.	Four	1-mL	samples	were	taken:	(1)	uninduced	sample	(i.e.,	before	IPTG	was	added),	(2)	a	sample	take	3	hours	after	the	induction	of	expression,	(3)	a	sample	taken	6	hours	after	the	induction	of	expression,	and	(4)	a	sample	of	the	culture	after	the	expressed	was	induced	overnight.	The	samples	were	centrifuged	(discarding	all	
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supernatant),	and	100μL	of	2x	SDS	buffer	was	added	to	each	sample.	Because	the	ODs	of	all	the	samples	were	the	same,	the	same	amount	of	buffer	was	added	to	each	sample	to	ensure	the	same	concentration	of	cell	contents	material	per	sample.	These	samples	were	heated	at	95°C	for	15	minutes,	vortexing	occasionally	to	lyse	the	cells.	Next,	the	samples	were	centrifuged	for	10	minutes,	and	only	the	supernatant	was	saved.	These	samples	were	then	used	to	run	two	15%	polyacrylamide	gels:	one	gel	for	Coomassie	staining	and	another	gel	for	a	Western	blot.	For	gels	that	were	transferred	for	a	Western	blot,	the	gel	was	transferred	onto	nitrocellulose	membrane	using	a	Mini-Vertical	PAGE/Blotting	System	(Bio-Rad).	The	gels	were	transferred	for	45	minutes	at	100	V.	The	membrane	was	placed	in	a	cassette	box	with	a	blocking	solution	made	with	5	g	dry	milk,	100mL	Tris-Buffer	Saline	(TBS),	and	100	μL	of	Tween.	This	was	incubated	on	a	rocker	at	15°C	for	45	minutes.	Next,	the	membrane	was	rinsed	three	times	with	TBS.	Then,	the	primary	antibody	solution	was	added,	which	contained	10	mL	TBS,	10	μL	of	Tween	and	5	μL	of	primary	mouse	antibody	for	a	1:2000	dilution	ratio	This	was	incubated	on	a	rocker	at	15°C	for	at	least	1	hour	and	sometimes	overnight.	After	incubation	with	primary	antibody,	mouse	antibody,	the	membrane	was	rinsed	with	TBS-T	three	times.	The	secondary	antibody	solution	was	made	with	10	mL	of	TBS-T,	0.5	g	dry	milk	and	2	μL	of	anti-mouse	secondary	antibody.	This	secondary	antibody	solution	was	added	and	incubated	on	a	rocker	at	15°C	for	at	least	one	hour.	The	secondary	antibody	was	then	removed.	It	was	then	rinsed	three	times	with	TBS	and	washed	for	one	hour	in	TBS	on	a	rocker	at	15°C.	The	blot	was	then	developed	by	adding	700	μL	of	Luminol	Enhancer	and	700	μL	of	Peroxide	Solution	and	visualized	on	the	GelDoc.		
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Optimization	of	Protein	Expression	Using	Glucose	and	pLysS	Two	different	variations	of	protein	expression	were	also	attempted	to	halt	the	leaky	expression	if	CRABP1	using	the	same	plasmid.	The	first	method	was	inducing	the	expression	of	CRABP1	in	the	presence	of	glucose. For	expression	in	the	presence	of	glucose,	we	conducted	this	experiment	as	described	above	except	in	the	presence	of	0%,	0.5%,	1%,	and	2%	glucose.	From	each	culture,	two	samples	were	taken:	(1)	an	uninduced	sample	and	(2)	a	sample	taken	3	hours	after	induction.	The	other	method	used	was	to	induce	expression	in	the	presence	of	lysozyme.	This	was	done	using	BL21(DE3)	cells	that	contain	a	pLysS	plasmid	that	expresses	T7	lysozyme	that	inhibits	expression	of	inducible	genes	prior	to	adding	IPTG.	Samples	taken	were	again	used	to	run	two	protein	gels	per	test,	using	one	for	Coomassie	staining	and	one	for	a	Western	blot.		
	
Subcloning	crabp1	Next,	we	obtained	three	different	expression	vectors	with	the	aim	of	cloning	the	
crabp1	gene	into	these	vectors.	The	expression	vectors	that	we	used	were	pET15b,	pRSF,	and	pRSF	Duet.	The	pET15-b	and	pRSF	Duet	include	a	His6	affinity	tag	that	can	be	added	to	the	expressed	protein.	This	His6	affinity	tag	can	be	used	later	during	the	protein	purification	process	using	affinity	chromatography.	The	cloning	process	involved	multiple	steps:	polymerase	chain	reaction	(PCR)	to	amplify	the	gene	of	interest	using	vector-specific	primers,	gel	purification	of	the	PCR	products,	restriction	digest	of	the	amplified	crabp1	gene	and	the	vectors	of	interest	using	the	appropriate	restriction	enzymes,	gel	purification	of	the	digested	products,	ligation	of	the	digested	vector	and	crabp1	gene,	and	
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transformation	of	the	ligated	vector	and	gene	into	DH5⍺	cells.	Any	positive	transformants	were	tested	through	screening	via	colony	PCR.		First,	PCR	was	used	to	amplify	crabp1	present	in	the	plasmid	template.	In	a	PCR	tube,	the	following	items	were	added:	2	μL	of	template	DNA,	5	μL	10x	Taq	Buffer,	with	4	μL	MgCl2,	1	μL	dNTP	mix,	2.5	μL	forward	primer,	2.5	μL	reverse	primer,	0.2	μL	Taq	DNA	polymerase,	and	32.8	μL	sterile	water.	A	control	was	made	by	replacing	the	template	DNA	with	sterile	water.	A	standard	PCR	protocol	was	used.	PCR	primers	were	made	to	contain	restriction	enzyme	sites	that	corresponded	to	each	vector	(Table	1).	The	PCR	products	were	then	visualized	using	agarose	gel	electrophoresis.	The	bands	from	the	gel	electrophoresis	that	corresponded	to	the	molecular	weight	of	the	crabp1	PCR	product	were	then	gel	purified	using	a	Wizard	SV	Gel	and	PCR	Clean-Up	System	(Promega).		This	was	followed	by	a	restriction	digest	using	the	proper	restriction	enzymes	specific	to	each	vector.	Both	the	crabp1	gene	and	vectors	were	digested.	Each	was	combined	with	1	uL	of	each	desired	restriction	enzyme,	3	μL	of	CutSmart,	and	the	remaining	volume	was	deionized	water	(30	μL	total	volume).	This	mixture	was	put	in	a	37°C	bath	for	at	least	one	hour.		
	 The	digests	were	again	run	on	agarose	gels	using	the	same	gel	electrophoresis	protocol	from	the	PCR	gel	electrophoresis,	and	the	resulting	bands	from	the	digested	
crabp1	genes	and	digested	vectors	were	then	gel	purified.	Next,	crabp1	was	ligated	into	each	of	the	vectors	in	a	series	of	experiments.	To	insert	the	crabp1	gene	into	the	desired	vector,	different	ratios	of	the	gene	and	desired	vector	were	used	and	subsequently	combined	with	DNA	ligase.	The	ratios	included:	a	1:1	plasmid	to	insert	ratio,	a	3:5	plasmid	
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to	insert	ratio,	and	a	1:7	plasmid	to	insert	ratio.	The	tubes	were	then	incubated	at	room	temperature	for	at	least	two	hours.	To	see	if	the	ligations	were	successful,	each	ligation	reaction	was	transformed	into	DH5⍺	cells.	The	cells	were	plated	on	LB	plates	with	proper	antibiotic	resistance	(see	table	1).	Along	with	plating	the	experimental	ligations,	positive	and	negative	control	ligations	were	also	plated.	Positive-control	ligations	were	made	by	using	an	uncut	vector,	and	negative	controls	were	made	using	digested	vectors	without	an	added	crabp1	gene.	Any	colonies	that	grew	on	the	plates	were	tested	via	colony	PCR	to	determine	if	the	gene	of	interest	was	present.	Colony	PCR	is	performed	by	picking	colonies	that	grew	on	the	resulting	plated	cultures	with	a	small	pipette	tip	and	inserting	a	part	of	the	colony	into	a	small	sample	of	hot	water	for	10	minutes.	This	sample	is	then	used	as	the	“DNA”	sample	for	the	previously	mentioned	PCR	protocol.	
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Results	The	purpose	of	these	experiments	was	to	overexpress	and	purify	CRABP1.	To	start	this,	IPTG	was	added	to	a	liquid	culture	of	BL21(DE3)	cells	transformed	with	the	pBS	
crabp1	plasmid	in	order	to	induce	expression	of	CRABP1.	A	Western	blot	showing	the	expression	of	the	CRABP1	protein	is	shown	in	Figure	2	with	a	single	band	observed	at	approximately	16	kDa,	the	presumed	molecular	weight	of	the	CRABP1	protein.	As	the	induction	time	increases,	the	CRABP1	bands	become	lighter	and	lighter.	Though	the	function	of	IPTG	is	to	induce	expression,	the	highest	expression	appears	to	occur	before	it	is	added.	It	is	hypothesized	that	the	CRABP1	protein	is	produced	before	induction	and	is	degrading	over	time.			 Because	there	was	no	increase	or	overexpression	of	CRABP1,	the	experiment	was	repeated	with	the	addition	of	glucose.	Different	concentrations	of	a	glucose	solution	(0.5%,	1%,	and	2%	glucose)	were	added	to	liquid	cultures	with	the	goal	of	inhibiting	leaky	expression	of	the	CRABP1	protein.	Two	protein	gels	were	run:	one	for	a	Coomassie	stain	(Figure	3)	and	one	for	a	Western	blot	(Figure	4).	In	Figure	3,	no	discernable	differences	could	be	observed	in	the	Coomassie	gel	when	comparing	expression	before	and	after	induction.	In	the	lanes	with	0.5%,	1%,	and	2%	glucose	concentration,	the	overall	protein	expression	of	the	cells	decreases	from	pre	to	post	induction.	Since	anti-CRABP1	from	mice	was	used	again	and	the	mass	of	CRABP1	is	16	kDa,	it	can	be	assumed	that	the	protein	in	the	bands	of	the	western	blot	is	CRABP1.	Similarly	to	Figure	2,	pre-induction	saw	more	expression	than	post-induction.	Since	glucose	is	supposed	to	prevent	leaky	expression,	there	should	be	very	little	to	no	CRABP1	present	in	the	pre-induction	lanes.		
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BL21(DE3)	cells	with	an	added	pLysS	plasmid,	which	expresses	lysozyme	in	order	to	inhibit	RNA	polymerase	before	the	cells	are	induced	with	IPTG,	were	induced	with	IPTG.	Samples	from	before	and	3	hours	after	induction	were	taken	and	run	on	an	SDS-PAGE	gel.	Figure	5	shows	Coomassie	stained	protein	gel	with	the	uninduced	in	lane	2	and	3	hours	post	induction	in	lane	3.	There	was	little	change	in	protein	expression	from	before	to	after	induction.		When	inducing	with	different	forms	of	leaky	expression	inhibition	failed	to	show	an	increase	in	expression,	the	crabp1	gene	was	subcloned	into	new	plasmids	in	order	to	see	if	those	might	work	better	for	expression.	Our	objective	was	to	subclone	the	crabp1	gene	into	three	new	vectors:	pET-15b,	pRSF-1	and	pRSF-Duet.		The	crapb1	gene	was	amplified	by	PCR	using	primers	that	had	specific	restriction	enzyme	sites	that	corresponded	to	the	different	plasmid	restriction	enzyme	sites	into	which	we	hoped	to	insert	the	gene.	Figure	6	shows	the	PCR	products	of	crabp1	with	pET-15b	and	pRSF-1	specific	primers,	on	an	agarose	gel.	For	lanes	2-7,	there	were	bright	bands	below	500	base	pairs,	assumed	to	be	crabp1.	Figure	7	shows	the	PCR	product	of	crabp1	using	primers	specific	for	the	pET-Duet	vector.	Lanes	2-4	contain	the	PCR	product,	which	all	show	crabp1	sized	bands.			 After	the	presumed	crabp1	DNA	bands	were	gel	purified,	the	crabp1	and	vectors	were	digested	with	their	corresponding	restriction	enzymes.	Figure	8	displays	the	results	of	the	restriction	digest	done	on	the	pET-Duet	and	pRSF-1	plasmids,	as	well	as	the	crabp1	PCR	product.	Figure	9	shows	the	restriction	of	pET-15b	and	the	crabp1	PCR	product.	The	pET-Duet	digestion	did	not	yield	a	significant	amount	of	digested	vector,	even	when	concentrations	of	vector	were	increased	in	the	digest	reactions	(Figure	8).	For	this	reason,	
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we	focused	our	subcloning	efforts	on	the	pRSF-1	and	pET-15b	vectors	from	this	point	forward.		After	the	pRSF-1	and	pET-15b	vectors	and	crabp1	were	successfully	digested	with	their	respective	restriction	enzymes,	the	samples	were	gel	purified,	ligated,	and	transformed	into	DH5α	cells.	The	ligation	of	crabp1	into	pET-15b	was	not	successful,	as	no	plated	cultures	grew.	The	plated	cultures	of	the	ligation	of	crabp1	did	accumulate	colonies	on	all	of	the	plates.	Figure	12	shows	the	results	of	the	colony	PCR	of	crabp1	ligated	into	pRSF-1	from	the	transformed	DH5α	cells.	Lanes	2-7	(gel	on	the	left)	and	lanes	2-7	(gel	on	the	right)	show	faint	bands	right	below	the	500	base-pair	mark,	thought	to	be	crabp1.	The	positive	and	negative	control	lanes	did	not	show	any	bands	corresponding	to	crabp1.			
Discussion	The	goal	of	this	research	was	to	express	and	purify	a	recombinant	form	of	the	CRABP1	protein	with	the	objective	of	gaining	a	better	understanding	of	the	biochemistry	of	the	protein.		The	first	objective	to	be	completed	was	to	express	CRABP1	in	BL21(DE3)	cells	using	IPTG	to	induce	its	expression.	When	IPTG	was	added	to	the	BL21(DE3)	cells	containing	the	pBS	plasmid	encoding	the	crabp1	gene,	the	expression	of	CRABP1	decreased,	as	shown	in	the	Western	blot	(Figure	2).	The	bands	were	observed	at	a	molecular	weight	between	15	and	16	kDa,	which	is	consistent	with	the	molecular	weight	of	the	CRABP1	protein,	15.556	kDa.	However,	it	was	expected	that	protein	expression	would	increase	upon	induction	and	that	we	would	observe	darker	bands	post-expression,	indicative	of	more	protein	being	produced	in	the	cells.	Instead,	the	addition	of	the	IPTG	had	no	effect,	as	protein	expression	either	decreased	or	the	protein	began	to	degrade	over	time.	It	is	not	entirely	clear	why	
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IPTG	induction	was	not	successful	with	this	plasmid.	In	E.	coli,	the	lac	operon	contains	the	gene	lacI,	which	expresses	the	lac	repressor.	The	lac	repressor	binds	to	the	lac	operator	and	inhibits	transcription	from	moving	to	the	promoter.	When	IPTG	is	added	to	E.	coli,	expression	is	induced	at	the	promoter	(Hansen	et	al.,	1998).		In	an	attempt	to	increase	the	expression	of	CRABP1	protein	in	these	cells	transformed	with	the	pBS	crabp1	plasmid,	glucose	was	added	to	the	culture	media.	Glucose	is	known	to	prevent	“leaky”	protein	expression	before	induction	(Novy	and	Morris,	2001).	Varying	percentages	of	glucose	were	added	(0%,	0.5%,	1%	and	2%)	to	the	cell	cultures	prior	to	induction	with	IPTG.	The	addition	of	glucose	did	not	appear	to	prevent	expression	prior	to	induction.	In	fact,	we	observed	a	decrease	in	expression	over	the	course	of	time,	regardless	of	the	percentage	of	glucose	added	to	the	media	(Figures	3	and	4).	These	results	were	similar	to	that	of	the	protein	expression	trials	in	the	absence	of	glucose	(Figure	2),	in	that	the	expression	seemed	to	decrease	post-induction	or	there	was	protein	degradation	over	time.		Next,	BL21(DE3)	pLysS	cells	were	used,	again	in	an	attempt	to	prevent	pre-induction	expression	of	the	protein.	This	was	executed	by	transforming	the	pBS	plasmid	with	crabp1	into	cells	containing	the	pLysS	plasmid.	This	plasmid	expresses	T7	lysozyme,	which	inhibits	the	expression	of	inducible	genes	before	IPTG	induction.	The	pLysS	experiments	were	conducted	by	collecting	samples	pre-induction	and	three	hours	post-induction	with	IPTG.	As	observed	in	the	previous	trials,	there	was	still	expression	before	induction	and	no	visible	increase	in	expression	after	induction.	In	fact,	protein	expression	seemed	to	decrease	over	time	(Figure	5).	
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Because	we	were	unable	to	achieve	inducible	expression	of	the	CRABP1	protein	in	the	pBS	plasmid,	our	next	step	was	to	clone	the	gene	into	a	different	plasmid,	which	would	serve	two	aims:	(1)	achieve	inducible	protein	expression	and	(2)	add	an	affinity	tag	to	the	protein,	which	would	ultimately	lead	to	more	efficient	purification.	We	had	three	expression	vectors	available	to	us:	pET15b,	pRSF-1,	and	pET-Duet.	The	crabp1	gene	was	first	amplified	using	pET15b,	pET-Duet	and	pRSF-1	specific	primers.	Primer	design	took	time	and	care,	and	this	process	had	to	be	repeated	after	our	first	attempt,	as	the	crabp1	gene	was	not	in-frame	with	the	encoded	purification	tags	on	our	first	attempt	at	primer	design	(data	not	shown).	However,	we	were	eventually	able	to	amplify	crabp1	using	appropriately	designed	primers	for	the	plasmids	we	wanted	to	use.		Our	attempts	at	digesting	the	different	plasmids	with	our	restriction	enzymes	of	interest	were,	in	part,	successful.	The	pRSF-1	and	pET-15b	plasmids	had	the	most	successful	digests,	whereas	the	pET-Duet	restriction	digest	did	not	work	as	well	as	seen	by	the	unconcentrated	double	band	seen	on	the	gel(Figure	8),	possibly	due	to	the	use	of	an	older	aliquot	of	the	restriction	enzyme.	Once	both	the	plasmids	and	crabp1	were	digested	and	gel-purified,	we	next	attempted	ligation.		The	digested	crabp1	insert	was	ligated	with	the	digested	plasmids.	We	attempted	these	ligations	many	times	using	a	variety	of	ratios	of	insert-to-plasmid.	Additionally,	we	tried	varying	lengths	of	time	for	these	ligations	and	different	aliquots	of	the	ligase	to	see	if	this	would	aid	in	successful	ligation	reactions.	These	ligations	were	transformed	into	BL21(DE3)	cells.	The	ligation	only	seemed	to	be	successful	using	the	pRSF-1	plasmid,	as	no	colonies	grew	on	the	plates	with	the	pET-15b	plasmid	and	insert.	In	addition,	we	also	noted	
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that	the	positive	control	plates	had	many	colonies	grow,	while	the	negative	control	plates	had	very	few	colonies.				Cells	from	the	resulting	pRSF-1	colonies	were	collected	for	colony	PCR.	The	results	of	the	colony	PCR	for	the	pRSF-crabp1	colonies	showed	bands	at	the	correct	molecular	weight	for	crabp1	from	all	tested	colonies	except	for	the	negative	and	positive	controls.	Though	the	bands	were	faint,	we	grew	up	two	of	these	colonies	and	performed	minipreps	to	get	concentrated	plasmid	DNA.	Our	last	experiments	included	testing	the	expression	of	one	of	the	pRSF-crabp1	plasmids,	though	we	did	not	see	overexpression	of	the	CRABP1	protein	in	Coomassie	gels	(data	not	shown).	Further	tests	with	respect	to	these	isolated	plasmids	will	include	sequencing	the	plasmids	and	also	performing	a	Western	blot	to	see	if	the	CRABP1	protein	is	expressed.		Once	the	gene	is	successfully	incorporated	into	an	expression	plasmid,	the	CRABP1	protein	will	then	be	purified.	The	protein	will	be	overexpressed,	the	cells	lysed	using	a	sonicator,	and	the	lysate	applied	to	a	nickel	resin	that	specifically	binds	to	the	His-tagged	protein.	Additional	purification	steps	may	be	necessary	depending	on	the	purity	of	the	protein,	which	can	be	assessed	by	running	a	Coomassie	protein	gel.	Should	we	not	have	efficient	lysis	of	the	cells,	an	alternative	method	for	acquiring	the	CRABP1	protein	is	to	use	a	signal	sequence	to	secrete	CRABP1	from	the	cells.	A	signal	sequence	is	an	extension	on	the	N-terminus	of	a	protein,	which	conveys	to	the	cellular	machinery	where	to	be	“sent”	(Martoglio,1998).	Such	a	sequence	could	be	used	to	secrete	the	protein	into	the	periplasmic	space,	which	would	allow	for	easier	extraction	from	the	bacterial	cell.		Though	we	spent	most	of	the	time	in	the	lab	working	on	the	subcloning	of	the	
crabp1	gene	into	different	plasmids,	there	are	many	experiments	that	we	hope	to	pursue	
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upon	successful	cloning	and	purification	of	the	CRABP1	protein.		The	experiments	that	we	envision	would	first	be	to	assess	the	protein’s	folding	using	techniques	that	might	include	circular	dichroism	or	differential	scanning	fluorimetry.	Non-bacterial	proteins	that	are	expressed	in	these	microorganisms	are	sometimes	misfolded,	and	before	testing	CRABP1’s	ability	to	bind	to	ligands	or	inhibitors	we	would	first	want	to	make	sure	that	it	was	folded.	The	purpose	of	finding	a	small	molecule	to	bind	to	CRABP1	would	be	to	free	up	retinoic	acid.	If,	using	a	small	molecule	library,	we	could	find	a	molecule	that	has	a	higher	affinity	to	CRABP1	than	retinoic	acid,	retinoic	acid	would	be	freed	up	to	accumulate	in	the	adipose	stromal	cells.	The	affinity	of	the	small	molecules	to	CRABP1	could	be	tested	by	using	a	thermal	shift	assay.	Lastly,	we	would	make	mutations	to	CRABP1	in	order	to	find	a	mutation	that	causes	CRABP1	to	have	the	inability	to	bind	to	retinoic	acid.	This	would	be	done	by	systematically	mutating	single	amino	acids	within	the	binding	pocket	for	retinoic	acid.	Once	a	promising	mutation	is	found,	the	mutated	CRABP1	would	be	tested	in	the	adipose	stromal	cells	to	assess	lipid	accumulation.		 Next,	the	purified	and	properly	folded	CRABP1	protein	could	be	screened	with	a	small-molecule	library	to	find	small	molecules	that	have	a	high	affinity	for	CRABP1.	It	was	found	in	a	previous	study	that	CRABP1	prevents	the	accumulation	of	retinoic	acid	in	adipose	stromal	cells	by	binding	to	and	sequestering	it.	The	goal	in	this	part	of	the	experiment	would	be	to	find	small	molecules	that	bind	to	CRABP1	and	have	a	higher	affinity	for	CRABP1	than	retinoic	acid	and	CRABP1.	The	affinity	of	the	small	molecules	to	CRABP1	could	be	tested	via	thermal	shift	assay	or	isothermal	titration	calorimetry	(ITC).	Then,	tests	could	be	done	with	these	molecules	in	vitro	using	techniques	such	as	a	lipid	accumulation	assay	to	see	whether	the	cells	can	regain	the	ability	to	accumulate	lipids.	It	is	
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hypothesized	that	CRABP1	would	bind	with	a	molecule	that	has	a	higher	affinity,	leaving	retinoic	acid	to	be	free	to	accumulate	in	the	adipose	stromal	cells.		 Lastly,	we	could	attempt	to	mutate	specific	amino	acids	to	see	if	any	mutations	cause	CRABP1	to	have	the	inability	to	bind	to	retinoic	acid.	In	a	normal	CRABP1	and	retinoic	acid	interaction,	the	hydrophobic	β-sheets	in	the	CRABP1	protein	encase	the	hydrophobic	tail	while	the	carboxylate	head	group	of	the	retinoic	acid	hydrogen	bonds	to	the	polar	amino	acids	in	the	CRABP1.	We	could	systematically	make	single	mutations	of	amino	acids,	specifically	within	the	retinoic	acid	binding	pocket	of	CRABP1,	to	determine	if	these	mutations	cause	a	decrease	in	affinity	between	CRABP1	and	retinoic	acid.	To	do	this,	site-directed	mutagenesis	could	be	used	on	the	plasmid	sequence	followed	by	expression	and	purification	of	the	mutated	CRABP1.	We	could	then	determine	if	the	mutated	protein	is	folded	correctly	and	test	the	affinity	of	retinoic	acid	to	the	mutated	CRABP1	protein.	Finally,	this	protein	could	then	be	tested	in	ASC-Ls	or	other	supporting	cells	to	observe	the	effectiveness	of	mutating	the	CRABP1	on	lipid	accumulation	in	adipose	stromal	cells.	Although	this	research	leaves	many	open-ended	questions	about	the	relationship	between	CRABP1	and	pregnancy	associated	breast	cancer	and	the	specific	role	that	it	plays,	these	questions	have	potential	to	encourage	research	to	improve	our	understanding	of	this	complex	disease.												
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Figures	and	Captions	
	
Table	1.	
Plasmid	 Antibiotic	Resistance	 Restriction	Enzymes	pBS	 Ampicillin	 N/A	pRSF-1	Duet	 Kanamycin	 PstI	and	HindIII	pET-1	Duet	 Ampicillin	 EcoRI	and	HindIII	pET15b	 Ampicillin	 NDEI	and	BamHI	
Table	1.	This	table	shows	the	specific	antibiotic	resistances	and	restriction	digest	enzymes	needed	for	all	plasmids	used.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	1.	Structure	of	CRABP1	bound	to	retinoic	acid.	Image	generated	by	WebGL	Protein	Viewer	using	the	atomic	coordinates	from	PDB	ID	1CBR.					
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Figure	2.	The	expression	of	CRABP1	in	BL21(DE3)	cells.	Lane	2	are	uninduced	cells,	Lane	3	are	cells	lysed	3	hours	post-induction,	Lane	4	are	cells	lysed	6	hours	post-induction,	and	Lane	5	are	cells	lysed	after	being	left	overnight	post-induction.				
	
Figures	3	and	4.	The	expression	of	CRABP1	in	BL21(DE3)	cells	with	the	addition	of	glucose.	The	lanes	for	both	are	as	follows:	(1)	molecular	weight	ladder	,	(2)	0%	glucose	uninduced,	(3)	0%	glucose	3	hours	post-induction,	(4)	0.5%	glucose	uninduced,	(5)	0.5%	glucose	3	hours	post-induction,	(6)	1%	glucose	uninduced,	(7)	1%	glucose	3	hours	post-induction,	(8)	2%	glucose	uninduced,	and	(9)	2%	glucose	3	hours	post-induction.	Figure	2	(left)	shows	the	Coomassie	stain	of	all	protein	expression	while	Figure	3	(right)	shows	the	expression	of	just	the	CRABP1	protein.	For	both	figures,	all	lanes	show	a	noticeable	decreased	in	expression	from	before	to	after	induction.		
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Figure	5.	The	Expression	of	CRABP1	in	pBS	with	BL21	cells	with	the	addition	of	pLysS	
plasmid.	Lane	1	contains	the	molecular	weight	marker,	lane	2	contains	the	uninduced	sample,	and	lane	3	contains	the	3-hour	post-induction	sample.	There	are	discernable	bands	before	and	after	induction	with	little	change	in	concentration	of	the	bands.			
		
Figure	6.	PCR	amplification	of	crabp1	using	pET-15b-	and	pRSF-1-specific	primers.	Lanes	1	and	8	contain	a	1kb	ladder.	Lanes	2-4	contain	the	amplified	crabp1	using	primers	designed	for	the	pET15b	plasmid.	Lanes	5-7	contain	the	amplified	crabp1	using	primers	specific	for	the	pRSF-1	plasmid.	Lanes	2-7	all	show	bright	bands	right	below	500	base	pairs	corresponding	to	the	crabp1	gene.			
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Figure	7.	PCR	amplification	of	crabp1	using	pET-Duet	specific	primers.	Lanes	1	and	5	contain	a	1kb	ladder.	Lanes	2-4	contain	the	amplified	crabp1	using	primers	specific	for	the	pET-Duet	plasmid.		The	most	intense	bands	in	lanes	2-4	are	located	below	500	base	pairs,	again	corresponding	to	the	
crabp1	gene.		
			
Figure	8.	Restriction	digest	of	pET-Duet,	pRSF-1	and	crabp1	with	EcoRI	and	HindIII.	Lanes	1	and	8	contain	a	1kb	ladder.	Lanes	2	and	3	contain	the	digested	pET-Duet	plasmid,	lanes	4	and	5	contain	the	digested	pRSF-1	plasmid	and	lanes	6	and	7	contain	the	digested	crabp1.				
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Figure	9.	Restriction	digest	of	pET-15b	plasmid	and	crabp1.	Lanes	1	and	6	contain	1kb	ladders.	Lanes	2	and	3	contain	the	digested	pET15b	plasmid	and	lanes	4	and	5	contain	the	digested	crabp1.				
		
Figure	10.	Restriction	digest	of	pRSF-1	plasmid	and	crabp1.		Lanes	1	and	6	contain	1kb	ladder,	lanes	2	and	3	contain	the	digested	pRSF-1	plasmid	with	bright	bands	at	about	4000	base	pairs	and	faint	bands	between	4000	and	5000	base	pairs.	Lanes	4	and	5	contain	the	digested	crabp1,	with	no	discernable	bands.	Though	no	digested	crabp1	is	observed	on	this	gel,	we	were	able	to	digest	the	gene	is	subsequent	experiments	to	be	utilized	in	ligation	reactions	(data	not	shown).		
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Figure	11.	Restriction	digest	of	crabp1	using	pRSF-1	and	pET-15b	enzymes.	Lanes	1	and	6	contain	1kb	ladder,	lanes	2	and	3	contain	the	digested	crabp1	using	the	BamHI	and	NDEI	restriction	enzymes	and	lanes	4	and	5	contain	the	digested	crabp1	using	HindIII	and	PstI.		
		
Figure	12.	Colony	PCR	of	crabp1	ligation	into	pRSF-1.	In	the	8-well	gel	(left)	lane	1	contains	a	1kb	ladder,	lanes	2-4	contain	1:1	plasmid	to	insert	ligation	samples	and	lanes	5-7	contain	3:5	plasmid	to	insert	ligation	samples.	In	the	10-well	gel	(right),	lane	1	contains	a	1kb	ladder,	lanes	2-4	contain	1:7	ligation	samples	plasmid	to	insert,	lane	8	contains	a	positive	control	and	lane	9	contains	a	negative	control.	There	are	faint	bands	below	the	500	base-pair	mark	in	lanes	2-7	of	both	gels.	Lanes	8	and	9	of	the	10-well	(right)	gel	do	not	show	any	bands.			
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